Skip to main content
Download PDF

A Novel Approach for Cancer Immunotherapy: Tumor Cells with Anchored Superantigen SEA Generate Effective Antitumor Immunity

Journal of Clinical Immunology volume 24, pages 294–301 (2004)Cite this article

Abstract

Murine B16 melanoma cell line is poorly immunogenic and highly aggressive. We recently reported that the transmembrane staphylococcal enterotoxin A (TM-SEA) anchors onto B16 cells and stimulates lymphocyte proliferation. The purpose of the study was to investigate whether vaccination with B16 cells bearing membrane-anchored TM-SEA fusion protein could cause tumor-specific immunity. Mice in the therapeutic vaccination group received B16 tumor inoculations, followed by treatment with B16-TM-SEA vaccine or control vaccines. Mice in the prophylactic vaccination group were given B16-TM-SEA vaccine or control vaccines, followed by challenge with wild type B16 or control EL4 cells. Significant tumor growth inhibition, prolongation of survival, and marked augmentation of NK and CTL activities were observed in mice which received B16-TM-SEA vaccine as compared to controls. Overall, our results suggest that the TM-SEA cellular vaccine is a novel and effective strategy for cancer immunotherapy.

REFERENCES

  1. Herberman RB, Reynolds CW, Ortaldo JR: Mechanism of cytotoxicity by natural killer (NK) cell. Annu Rev Immunol 4:651-680, 1986

    Google Scholar 

  2. Doherty PC, Christensen JP: Accessing complexity: The dynamics of virus-specific T-cell responses. Annu Rev Immunol 18:561-592, 2000

    Google Scholar 

  3. Ostrand-Rosenberg S: Tumor immunotherapy: The tumor cell as antigen-presenting cell. Curr Opin Immunol 6:722-727, 1994

    Google Scholar 

  4. Fischer H, Dohlsten M, Andersson U, Hedlund G, Ericsson P, Hansson J, Sjogren HO: Production of TNF-α and TNF-β by staphylococcal enterotoxin A activated human cells. J Immunol 144:4663-4669, 1990

    Google Scholar 

  5. Gjorloff A, Fischer H, Hedlund G, Hansson J, Kenney JS, Allison AC, Sjogren HO, Dohlsten M: Induction of interleukin-1 in human monocytes by the superantigen staphylococcal enterotoxin A requires the participation of T-cells. Cell Immunol 137:61-71, 1991

    Google Scholar 

  6. Johnson HM, Russell JK, Pontzer CH: Staphylococcal enterotoxin microbial superantigens. FASEB J 5:2706-2712, 1991

    Google Scholar 

  7. Dohlsten M, Abrahmsen L, Bjork P, Lando PA, Hedlund G, Forsberg G, Brodin T, Gascoigne NR, Forberg C, Lind P, Kalland T: Monoclonal abtibody-superabtigen fusion protein: Tumor-specific agents for T-cell-based tumor therapy. Proc Natl Acad Sci USA 91:8945-8949, 1994

    Google Scholar 

  8. Ihle J, Holzer U, Krull F, Dohlsten M, Kalland T, Niethammer D, Dannecker GE: Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines. Cancer Res 55: 623-628, 1995

    Google Scholar 

  9. Dohlsten M, Hansson J, Ohlsson L, Litton M, Kalland T: Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc Natl Acad Sci USA 92:9791-9795, 1995

    Google Scholar 

  10. Rosendahl A, Hansson J, Sundstedt A, Kalland T, Dohlsten M: Immune response during tumor therapy with antibody-superantigen fusion proteins. Int J Cancer 68:109-113, 1996

    Google Scholar 

  11. Rosendahl A, Kristensson K, Hansson J, Riesbeck K, Kalland T, Dohlsten M: Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens. J Immunol 160:5309-5313, 1998

    Google Scholar 

  12. Rosendahl A, Kristensson K, Carlsson M, Skartved NJ, Riesbeck K, Sogaard M, Dohlsten M: Long-term survival and complete cures of B16 melanoma-carrying animals after therapy with tumor-targeted IL-2 and SEA. Int J Cancer 81:156-163, 1999

    Google Scholar 

  13. Litton MJ, Dohlsten M, Lando PA, Kalland T, Ohlsson L, Andersson J, Andersson U: Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Eur J Immunol 26:1-9, 1996

    Google Scholar 

  14. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K: Similarity of protein encoded by the human c-erb-B2 gene to epidermal growth factor receptor. Nature 319:230-234, 1986

    Google Scholar 

  15. Sharpe S, Barber KR, Grant CW: Val (659)-Glu mutation within the transmembrane domain of ErbB-2: Effects measured by (2)H NMR in fluid phospholipid bilayers. Biochemistry 39:6572-6580, 2000

    Google Scholar 

  16. Ma W, Yu H, Wang Q, Bao J, Yan J, Jin H: In vitro Biological activities of transmembrane superantigen Staphylococcal Enterotoxin A fusion protein. Cancer Immunol Immunother 53:118-124, 2004

    Google Scholar 

  17. Kim SY, Lee SE, Kim YR, Kim CM, Ryu PY, Choy HE, Chung SS, Rhee JH: Regulation of Vibrio vulnificus virulence by the LuxS quorum-sensing system. Mol Microbiol 48:1647-1664, 2003

    Google Scholar 

  18. Hernandez JM, Bui MH, Han KR, Mukouyama H, Freitas DG, Nguyen D, Caliliw R, Shintaku PI, Paik SH, Tso CL, Figlin RA, Belldegrun AS: Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. Clin Cancer Res 9:1906-1916, 2003

    Google Scholar 

  19. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH: Ligands for the murine NKG2D receptor: Expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 1:119-126, 2000

    Google Scholar 

  20. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH: Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165-171, 2001

    Google Scholar 

  21. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM: In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA 97:2731-2736, 2000

    Google Scholar 

  22. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097-2100, 2002

    Google Scholar 

  23. Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM: Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 163:6292-6300, 1999

    Google Scholar 

  24. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A: Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 97:12198-12203, 2000

    Google Scholar 

  25. Ferrone S, Marincola FM: Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487-494, 1995

    Google Scholar 

  26. Ruiz-Cabello F, Garrido F: HLA and cancer: From research to clinical impact. Immunol Today 19:539-542, 1998

    Google Scholar 

  27. Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P: Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 160:1750-1758, 1998

    Google Scholar 

  28. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999

    Google Scholar 

  29. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998

    Google Scholar 

  30. Litton MJ, Dohlsten M, Lando PA, Kalland T, Ohlsson L, Andersson J, Andersson U: Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Eur J Immunol 26:1-9, 1996

    Google Scholar 

  31. Litton MJ, Dohlsten M, Rosendahl A, Ohlsson L, Sogaard M, Andersson J, Andersson U: The distinct role of CD4+ and CD8+ T-cells during the anti-tumor effects of targeted superantigens. Br J Cancer 81:359-366, 1999

    Google Scholar 

  32. Rosendahl A, Kristensson K, Hansson J, Riesbeck K, Kalland T, Dohlsten M: Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens. J Immunol 160:5309-5313, 1998

    Google Scholar 

  33. Nielsen SE, Zeuthen J, Lund B, Persson B, Alenfall J, Hansen HH: Phase I study of single, escalating doses of a superantigen-antibody fusion protein (PNU-214565) in patients with advanced colorectal or pancreatic carcinoma. J Immunother 23:146-153, 2000

    Google Scholar 

  34. Wahlsten JL, Mills CD, Ramakrishnan S: Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells. J Immunol 161:6761-6767, 1998

    Google Scholar 

  35. Wang Q, Yu H, Zhang L, Ju D, Pan J, Xia D, He L, Wang J, Cao X: Vaccination with IL-18 gene-modified, superantigen-coated tumor cells elicits potent antitumor immune response. J Cancer Res Clin Oncol 127:718-726, 2001

    Google Scholar 

  36. Forsberg G, Ohlsson L, Brodin T, Bjork P, Lando PA, Shaw D, Stern PL, Dohlsten M: Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br J Cancer 85:129-136, 2001

    Google Scholar 

Download references

Author information

Affiliations

  1. Cancer Institute, Zhejiang University, Hangzhou, People's Republic of China

    Wenxue Ma, Hai Yu & Hongchuan Jin

  2. Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska

    Qingqing Wang

  3. Institute of Immunology, Zhejiang University, Hangzhou, People's Republic of China

    Wenxue Ma & Joyce Solheim

  4. Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska

    Vinod Labhasetwar

Authors
  1. Wenxue Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hai Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qingqing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hongchuan Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joyce Solheim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vinod Labhasetwar
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ma, W., Yu, H., Wang, Q. et al. A Novel Approach for Cancer Immunotherapy: Tumor Cells with Anchored Superantigen SEA Generate Effective Antitumor Immunity. J Clin Immunol 24, 294–301 (2004). https://doi.org/10.1023/B:JOCI.0000025451.41948.94

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:JOCI.0000025451.41948.94

  • Superantigen
  • transmembrane
  • vaccine
  • immune response
  • melanoma